{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+and+Severe+Active+Rheumatoid+Arthritis&page=3",
    "query": {
      "condition": "Moderate and Severe Active Rheumatoid Arthritis",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+and+Severe+Active+Rheumatoid+Arthritis&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+and+Severe+Active+Rheumatoid+Arthritis&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T23:34:12.180Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00106574",
      "title": "A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab [RoActemra/Actemra]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1220,
      "start_date": "2005-04",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 76,
      "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106574"
    },
    {
      "nct_id": "NCT02706873",
      "title": "A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo to Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1002,
      "start_date": "2016-02-23",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 32,
      "location_summary": "La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706873"
    },
    {
      "nct_id": "NCT02638259",
      "title": "Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "GP2015",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2015-02-21",
      "completion_date": "2017-06-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-19",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 26,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Van Nuys",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02638259"
    },
    {
      "nct_id": "NCT03970837",
      "title": "Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1764,
      "start_date": "2019-06-05",
      "completion_date": "2023-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 64,
      "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970837"
    },
    {
      "nct_id": "NCT03120949",
      "title": "Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Olokizumab 64 mg SC q4w",
          "type": "DRUG"
        },
        {
          "name": "Olokizumab 64 mg SC q2w",
          "type": "DRUG"
        },
        {
          "name": "Concomitant treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm International, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2106,
      "start_date": "2017-07-04",
      "completion_date": "2021-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-12",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 71,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 61 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03120949"
    },
    {
      "nct_id": "NCT06104124",
      "title": "A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sjogren's Syndrome"
      ],
      "interventions": [
        {
          "name": "Dazodalibep",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 651,
      "start_date": "2024-01-24",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 37,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104124"
    },
    {
      "nct_id": "NCT03357471",
      "title": "Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate and Severe Active Rheumatoid Arthritis",
        "Active Psoriatic Arthritis",
        "Active Ankylosing Spondylitis",
        "Moderately to Severely Active Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "e-Device",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2017-11-03",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2019-10-25",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 22,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03357471"
    },
    {
      "nct_id": "NCT02889796",
      "title": "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match adalimumab",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1759,
      "start_date": "2016-08-30",
      "completion_date": "2019-06-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 48,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889796"
    },
    {
      "nct_id": "NCT07276581",
      "title": "A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "AZD1163",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2025-12-15",
      "completion_date": "2028-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 29,
      "location_summary": "Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07276581"
    },
    {
      "nct_id": "NCT01232569",
      "title": "A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab 162 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 656,
      "start_date": "2011-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-07-29",
      "last_synced_at": "2026-10-11T23:34:12.180Z",
      "location_count": 44,
      "location_summary": "Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01232569"
    }
  ]
}